Mind Medicine (MindMed) (NASDAQ:MNMD) and Tauriga Sciences (OTCMKTS:TAUG) Head-To-Head Analysis

Mind Medicine (MindMed) (NASDAQ:MNMD) and Tauriga Sciences (OTCMKTS:TAUG) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Profitability

This table compares Mind Medicine (MindMed) and Tauriga Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mind Medicine (MindMed)	N/A	-47.56%	-35.55%
Tauriga Sciences	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations for Mind Medicine (MindMed) and Tauriga Sciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mind Medicine (MindMed)	0	0	10	3	3.23
Tauriga Sciences	0	0	0	0	0.00

Mind Medicine (MindMed) presently has a consensus target price of $26.33, suggesting a potential upside of 291.87%. Given Mind Medicine (MindMed)’s stronger consensus rating and higher probable upside, research analysts clearly believe Mind Medicine (MindMed) is more favorable than Tauriga Sciences.

Valuation & Earnings

This table compares Mind Medicine (MindMed) and Tauriga Sciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mind Medicine (MindMed)	N/A	N/A	-$95.73 million	($2.26)	-2.97
Tauriga Sciences	N/A	N/A	N/A	N/A	N/A

Institutional and Insider Ownership

27.9% of Mind Medicine (MindMed) shares are held by institutional investors. 2.3% of Mind Medicine (MindMed) shares are held by company insiders. Comparatively, 3.5% of Tauriga Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Mind Medicine (MindMed) beats Tauriga Sciences on 5 of the 8 factors compared between the two stocks.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

About Tauriga Sciences

Tauriga Sciences, Inc. produces and sells cannabidiol infused chewing gum under the Tauri-Gum brand name. It also develops anti-nausea products; and skin care products include CBD facemasks; CBD daily moisturizer; CBD anti-wrinkle dream, hand, and foot cream with hemp seed oil; CBD massage and body oil; CBD body revive roll-on; CBD transdermal patch; and CBD body spray. In addition, the company offers rainbow deluxe sampler pack, CBD non-GMO dietary supplements, and CBD scented bath bombs. It sells its products through e-commerce, distributors, and wholesale channels. The company has a collaboration agreement with Aegea Biotechnologies, Inc. to develop a rapid, multiplexed COVID-19 (novel coronavirus) test. Tauriga Sciences, Inc. was founded in 2001 and is headquartered in Wappingers Falls, New York.